PharmAla positioned to supply U.S. expanded access pathway for MDMA

PharmAla (MDXXF) Biotech responded to the Executive Order signed on April 18, 2026 by the President of the United States, which directs the U.S. Food and Drug Administration and the U.S. Drug Enforcement Administration to establish a pathway for eligible patients to access investigational psychedelic drugs, and directs the FDA Commissioner to issue National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designation.